Krystal Biotech rises on FDA nod for skin disorder gene therapy

Krystal Biotech

19/05/2023 19:27

** Shares of biotechnology co Krystal Biotech Inc  KRYS.O 
up 6.2% at about $93
    ** Co announces U.S. FDA approval for its Vyjuvek treatment
in patients six months of age or older with dystrophic
epidermolysis bullosa (DEB), a genetic skin disorder affecting
skin and nails that usually presents at birth
    ** KRYS expects treatment to be available in U.S. in Q3 2023
    ** Expects to start official Marketing Authorization
Application procedure for treatment in Europe in H2 2023 with a
potential approval in 2024 - co
    ** KRYS up about 18.1% YTD

 (Reporting by Vaibhav  Sadhamta)
 ((Vaibhav.Sadhamta@thomsonreuters.com;))